Sodium Fluoride F-18

also known as 18F-NaF · F-18 NaF · NaF · F-18 sodium fluoride · Fluorine F 18 Sodium Fluoride · Sodium Fluoride

Investigated by: National Cancer Institute (NCI) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Emory University · HTA Co., Ltd. · Stanford University

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	FLUORINE F-18	—	1972-02-24	fda.gov ↗

Trials 7 · a red edge is where a trial was stopped

today

US approved 1972

NCT06914999 · Ph 0 NCT05614518 · Ph 3 NCT03619655 · Ph 1 NCT03173924 · Ph 2 NCT03497377 · Ph 1 NCT02429804 · Ph 1 NCT01237054 · Ph 2

19711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06914999	Dec 2024 → Aug 2026 overdue	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oropharynx squamous cell carcinoma	Emory University	Recruiting	No outcome recorded
Phase 13 trials
Phase 1	NCT03619655	Nov 2019 → Nov 2022	prostate cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 1	NCT03497377	May 2016 → Apr 2020	metastatic prostate carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT02429804	Apr 2015 → May 2017	hormone-resistant prostate carcinoma, metastatic carcinoma in the bone, metastatic prostate carcinoma	Stanford University	Terminated	No outcome recorded
Phase 22 trials
Phase 2	NCT03173924	Jun 2017 → Feb 2028 expected	metastatic prostate carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT01237054	Oct 2010 → Aug 2011	monoclonal gammopathy of uncertain significance, smoldering plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT05614518	Mar 2021 → Jun 2022	musculoskeletal system cancer	HTA Co., Ltd.	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04981509 Background	Jun 2022 → Dec 2027 expected	hereditary leiomyomatosis and renal cell cancer, papillary renal cell carcinoma	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT01240551 Comparator	Nov 2010 → May 2013	prostate cancer	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	Sodium Fluoride F-18	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04981509 ↗ 2 NCT06914999 ↗ NCT05614518 ↗
Known as	18F-NaF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03173924 ↗ 2 NCT03619655 ↗ NCT03497377 ↗
Known as	F-18 NaF	“The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus” NCT01237054 ↗ 1 NCT01240551 ↗
Known as	F-18 sodium fluoride	“F-18 sodium fluoride (NaF) is a PET radiopharmaceutical” NCT01240551 ↗
Known as	Fluorine F 18 Sodium Fluoride	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02429804 ↗
Known as	NaF	“F-18 sodium fluoride (NaF) is a PET radiopharmaceutical” NCT01240551 ↗ 1 “Sodium Fluoride (NaF)-PET/CT imaging” NCT03497377 ↗
Known as	Sodium Fluoride	“Sodium Fluoride (NaF)-PET/CT imaging” NCT03497377 ↗
Modality	Diagnostic / imaging agent	“a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT)” NCT01237054 ↗
Route	Intravenous	“F-18 NaF IV (intravenous) bolus” NCT01237054 ↗